uu.seUppsala universitets publikasjoner
Endre søk
Begrens søket
12 1 - 50 of 73
RefereraExporteraLink til resultatlisten
Permanent link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Treff pr side
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sortering
  • Standard (Relevans)
  • Forfatter A-Ø
  • Forfatter Ø-A
  • Tittel A-Ø
  • Tittel Ø-A
  • Type publikasjon A-Ø
  • Type publikasjon Ø-A
  • Eldste først
  • Nyeste først
  • Skapad (Eldste først)
  • Skapad (Nyeste først)
  • Senast uppdaterad (Eldste først)
  • Senast uppdaterad (Nyeste først)
  • Disputationsdatum (tidligste først)
  • Disputationsdatum (siste først)
  • Standard (Relevans)
  • Forfatter A-Ø
  • Forfatter Ø-A
  • Tittel A-Ø
  • Tittel Ø-A
  • Type publikasjon A-Ø
  • Type publikasjon Ø-A
  • Eldste først
  • Nyeste først
  • Skapad (Eldste først)
  • Skapad (Nyeste først)
  • Senast uppdaterad (Eldste først)
  • Senast uppdaterad (Nyeste først)
  • Disputationsdatum (tidligste først)
  • Disputationsdatum (siste først)
Merk
Maxantalet träffar du kan exportera från sökgränssnittet är 250. Vid större uttag använd dig av utsökningar.
  • 1.
    Almqvist, Catarina
    et al.
    Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Karolinska Univ Hosp, Lung & Allergy Unit, Astrid Lindgren Childrens Hosp, Stockholm, Sweden..
    Olsson, Henrik
    Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden..
    Fall, Tove
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper. Uppsala universitet, Science for Life Laboratory, SciLifeLab.
    Lundholm, Cecilia
    Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden..
    Sibship and risk of asthma in a total population: A disease comparative approach2016Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 138, nr 4, s. 1219-1222Artikkel i tidsskrift (Fagfellevurdert)
  • 2.
    Amaral, Andre F. S.
    et al.
    Univ London Imperial Coll Sci Technol & Med, Resp Epidemiol Occupat Med & Publ Hlth, Natl Heart & Lung Inst, Emmanuel Kaye Bldg,1B Manresa Rd, London SW3 6LR, England..
    Newson, Roger B.
    Univ London Imperial Coll Sci Technol & Med, Resp Epidemiol Occupat Med & Publ Hlth, Natl Heart & Lung Inst, Emmanuel Kaye Bldg,1B Manresa Rd, London SW3 6LR, England.;Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Publ Hlth, Sch Publ Hlth, London, England..
    Abramson, Michael J.
    Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia..
    Anto, Josep M.
    Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.;IMIM Hosp del Mar, Med Res Inst, Barcelona, Spain.;UPF, Barcelona, Spain.;CIBERESP, Madrid, Spain..
    Bono, Roberto
    Univ Turin, Dept Publ Hlth & Pediat, Turin, Italy..
    Corsico, Angelo G.
    Univ Pavia, Div Resp Dis, IRCCS Policlin San Matteo Fdn, Via Palestro 3, I-27100 Pavia, Italy..
    de Marco, Roberto
    Univ Verona, Unit Epidemiol & Med Stat, Dept Publ Hlth & Community Med, I-37100 Verona, Italy..
    Demoly, Pascal
    CHU Montpellier, Dept Pulmonol, Div Allergy, Arnaud de Villeneuve Hosp, Paris, France.;INSERM, EPAR Team, UMR S 1136, Paris, France..
    Forsberg, Bertil
    Umea Univ, Div Occupat & Environm Med, Dept Publ Hlth & Clin Med, Umea, Sweden..
    Gislason, Thorarinn
    Univ Iceland, Fac Med, Reykjavik, Iceland.;Natl Univ Hosp Iceland, Landspitali, Dept Resp Med & Sleep, Reykjavik, Iceland..
    Heinrich, Joachim
    Helmholtz Zentrum, Inst Epidemiol 1, Munich, Germany.;Univ Munich, Inst & Outpatient Clin Occupat Social & Environm, Inner City Clin, Univ Hosp Munich, Munich, Germany..
    Huerta, Ismael
    Dept Hlth Asturias, Directorate Gen Publ Hlth, Epidemiol Surveillance Sect, Oviedo, Spain..
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Jogi, Rain
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lung- allergi- och sömnforskning. Tartu Univ Hosp, Lung Clin, Tartu, Estonia..
    Kim, Jeong-Lim
    Univ Gothenburg, Dept Publich Hlth & Community Med, Sahlgrenska Acad, Gothenburg, Sweden..
    Maldonado, Jose
    Univ Hosp Huelva, Unit Clin Management Pneumol & Allergy, Huelva, Spain..
    Rovira, Jesus Martinez-Moratalla
    Univ Hosp Albacete, Unit Pneumol, Albacete, Spain..
    Neukirch, Catherine
    INSERM, UMR1152, Paris, France.;Univ Paris 07, UMR1152, Paris, France..
    Nowak, Dennis
    Univ Munich, Inst & Outpatient Clin Occupat Social & Environm, Inner City Clin, Univ Hosp Munich, Munich, Germany.;German Ctr Lung Res, Munich, Germany..
    Pin, Isabelle
    CHU Grenoble, Pole Couple Enfants, Pediat, F-38043 Grenoble, France.;Inst Albert Bonniot, INSERM, U823, Grenoble, France.;Univ Grenoble 1, Grenoble, France..
    Probst-Hensch, Nicole
    Swiss Trop & Publ Hlth Inst, Basel, Switzerland.;Univ Basel, Basel, Switzerland..
    Raherison-Semjen, Chantal
    Bordeaux Univ, Inst Publ Hlth & Epidemiol, INSERM, U897, Bordeaux, France..
    Svanes, Cecilie
    Univ Bergen, Ctr Int Hlth, Bergen, Norway.;Haukeland Hosp, Dept Occupat Med, N-5021 Bergen, Norway..
    Landa, Isabel Urrutia
    Galdakao Hosp, Dept Pneumol, Bizkaia, Spain..
    van Ree, Ronald
    Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.;Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands..
    Versteeg, Serge A.
    Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands..
    Weyler, Joost
    Univ Antwerp, Epidemiol & Social Med, B-2020 Antwerp, Belgium.;Univ Antwerp, StatUA Stat Ctr, B-2020 Antwerp, Belgium..
    Zock, Jan-Paul
    Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.;UPF, Barcelona, Spain.;CIBERESP, Madrid, Spain..
    Burney, Peter G. J.
    Univ London Imperial Coll Sci Technol & Med, Resp Epidemiol Occupat Med & Publ Hlth, Natl Heart & Lung Inst, Emmanuel Kaye Bldg,1B Manresa Rd, London SW3 6LR, England..
    Jarvis, Deborah L.
    Univ London Imperial Coll Sci Technol & Med, Resp Epidemiol Occupat Med & Publ Hlth, Natl Heart & Lung Inst, Emmanuel Kaye Bldg,1B Manresa Rd, London SW3 6LR, England..
    Changes in IgE sensitization and total IgE levels over 20 years of follow-up2016Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 137, nr 6, s. 1788-1795Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Cross-sectional studies have reported a lower prevalence of sensitization in older adults, but few longitudinal studies have examined whether this is an aging or a year-of-birth cohort effect. Objective: We sought to assess changes in sensitization and total IgE levels in a cohort of European adults as they aged over a 20-year period. Methods: Levels of serum specific IgE to common aeroallergens (house dust mite, cat, and grass) and total IgE levels were measured in 3206 adults from 25 centers in the European Community Respiratory Health Survey on 3 occasions over 20 years. Changes in sensitization and total IgE levels were analyzed by using regression analysis corrected for potential differences in laboratory equipment and by using inverse sampling probability weights to account for nonresponse. Results: Over the 20-year follow-up, the prevalence of sensitization to at least 1 of the 3 allergens decreased from 29.4% to 24.8% (-4.6%; 95% CI, -7.0% to -2.1%). The prevalence of sensitization to house dust mite (-4.3%; 95% CI, -6.0% to -2.6%) and cat (-2.1%; 95% CI, -3.6% to -0.7%) decreased more than sensitization to grass (-0.6%; 95% CI, -2.5% to 1.3%). Age-specific prevalence of sensitization to house dust mite and cat did not differ between year-of-birth cohorts, but sensitization to grass was most prevalent in the most recent ones. Overall, total IgE levels decreased significantly (geometric mean ratio, 0.63; 95% CI, 0.58-0.68) at all ages in all year-of-birth cohorts. Conclusion: Aging was associated with lower levels of sensitization, especially to house dust mite and cat, after the age of 20 years.

  • 3.
    Amin, Kawa
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Harvima, Ilkka
    Venge, Per
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Nilsson, Gunnar
    CC chemokine receptors CCR1 and CCR4 are expressed on airway mast cells in allergic asthma2005Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 116, nr 6, s. 1383-1386Artikkel i tidsskrift (Annet vitenskapelig)
  • 4. Ando, Hitoshi
    et al.
    Movérare, Robert
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Kondo, Yasuto
    Tsuge, Ikuya
    Tanaka, Akira
    Borres, Magnus P.
    Urisu, Atsuo
    Utility of ovomucoid-specific IgE concentrations in predicting symptomatic egg allergy2008Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 122, nr 3, s. 583-588Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: Children with allergy to raw egg white might tolerate low amounts of heated egg. Ovomucoid-specific IgE antibodies have been suggested to be predictors of whether children could tolerate heat-treated egg. OBJECTIVE: The aim was to evaluate the clinical usefulness and added diagnostic value of measurements of IgE antibodies to egg white, ovalbumin, and ovomucoid in children with egg allergy. METHODS: One hundred eight patients (median age, 34.5 months) with suspected egg allergy underwent double-blind, placebo-controlled food challenges with raw and heated egg. The outcomes of the challenges were related to the serum concentration of specific IgE antibodies and total IgE by using ImmunoCAP. RESULTS: Reactions to heated egg white were observed in 38 patients (considered allergic to raw and heated egg), 29 patients reacted to only raw egg white, and 41 patients were tolerant. Correlation was observed between the serologic parameters studied. Receiver operating characteristic analysis showed that egg white ImmunoCAP was useful in the diagnosis of allergy to raw egg white. The positive decision point, based on 95% clinical specificity, was 7.4 kU(A)/L, and the negative decision point, based on 95% clinical sensitivity, was 0.6 kU(A)/L. For reaction to heated egg white, ovomucoid ImmunoCAP was superior. The positive decision point was 10.8 kU(A)/L, and the negative decision point was 1.2 kU(A)/L. CONCLUSIONS: Quantitative measurements of specific IgE antibodies to both egg white and ovomucoid and the evaluation against the suggested positive and negative decision points for specific IgE will be useful in the diagnosis of egg allergy.

  • 5.
    Andorf, Sandra
    et al.
    Stanford Univ, Stanford, CA 94305 USA..
    Borres, Magnus P
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa. Thermo Fisher Sci, Uppsala, Sweden..
    Block, Whitney
    Stanford Univ, Stanford, CA 94305 USA..
    Lidholm, Jonas
    Thermo Fisher Sci, Uppsala, Sweden..
    Jones, Joseph E.
    Thermo Fisher Sci, Portage, MI USA..
    Galli, Stephen J.
    Stanford Univ, Stanford, CA 94305 USA..
    Chinthrajah, R. Sharon
    Stanford Univ, Stanford, CA 94305 USA..
    Nadeau, Kari C.
    Stanford Univ, Stanford, CA 94305 USA..
    Characterization of multifood allergic children based on clinical and serological data2017Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 139, nr 2, s. AB140-AB140Artikkel i tidsskrift (Annet vitenskapelig)
  • 6.
    Aranda, Carolina S.
    et al.
    Univ Fed Sao Paulo, Sao Paulo, Brazil..
    Cocco, Renata
    Univ Fed Sao Paulo, Sao Paulo, Brazil..
    Pierotti, Felipe
    Univ Fed Sao Paulo, Sao Paulo, Brazil..
    Mallozi, Marcia Carvalho
    Univ Fed Sao Paulo, Planalto Paulista, Brazil..
    Wandalsen, Neusa F.
    Fac Med ABC, Santo Andre, Brazil..
    Franco, Jackeline Motta
    Univ Fed Sergipe, Aracaju, Brazil..
    Moraes, Lillian L.
    Univ Fed Mato Grosso, Cuiaba, Brazil..
    Goudouris, Ekaterine S.
    Univ Fed Rio de Janeiro, IPPMG, Rio de Janeiro, Brazil..
    Porto Neto, Arnaldo Carlos
    Sch Med UPF, Passo Fundo, Brazil..
    Sarinho, Emanuel S.
    Univ Fed Pernambuco, Recife, PE, Brazil..
    Rosario, Nelson Augusto
    Univ Fed Parana, Curitiba, Parana, Brazil..
    Pastorino, Antonio Carlos
    Univ Sao Paulo, Santana, Brazil..
    Sano, Flavio
    Hosp Nipo Brasileiro, Sao Paulo, Brazil..
    Freitas Silva Chavarria, Maria Leticia
    Edificio Clin, Goiania, Go, Brazil..
    Borres, Magnus
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Forskargrupper (Inst. för kvinnor och barns hälsa), Pediatrisk inflammationsforskning. Thermofisher Sci, Uppsala, Sweden..
    Sole, Dirceu
    Univ Fed Sao Paulo, Sao Paulo, Brazil..
    Allergic diseases in childhood: What allergic sensitization can teach us?2018Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 141, nr 2, s. AB281-AB281Artikkel i tidsskrift (Annet vitenskapelig)
  • 7.
    Bedard, Annabelle
    et al.
    ISGlobal, Barcelona, Spain;UPF, Barcelona, Spain;CIBERESP, Barcelona, Spain.
    Basagana, Xavier
    ISGlobal, Barcelona, Spain;UPF, Barcelona, Spain;CIBERESP, Barcelona, Spain.
    Anto, Josep M.
    ISGlobal, Barcelona, Spain;UPF, Barcelona, Spain;CIBERESP, Barcelona, Spain.
    Garcia-Aymerich, Judith
    ISGlobal, Barcelona, Spain;UPF, Barcelona, Spain;CIBERESP, Barcelona, Spain.
    Devillier, Philippe
    Univ Paris Saclay, Hop Foch, UPRES EA220, Pole Malad Voies Resp, Suresnes, France.
    Arnavielhe, Sylvie
    INNOV, KYomed, Montpellier, France.
    Bedbrook, Anna
    MACVIA France, Fdn Partenariale FMC VIA LR, Montpellier, France.
    Onorato, Gabrielle L.
    MACVIA France, Fdn Partenariale FMC VIA LR, Montpellier, France.
    Czarlewski, Wienczyslawa
    Med Consulting Czarlewski, Levallois Perret, France.
    Murray, Ruth
    MedScript, Med Commun Consultant, Dundalk, Ireland;OPC, Cambridge, England.
    Almeida, Rute
    Univ Porto, Fac Med, Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal;Medida, Porto, Portugal.
    Fonseca, Joao
    Univ Porto, Fac Med, Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal;Medida, Porto, Portugal.
    Costa, Elisio
    Univ Porto, Porto4Ageing, Fac Pharm, REQUINTE,UCIBIO, Porto, Portugal;Univ Porto, Porto4Ageing, Competence Ctr Act & Hlth Ageing, Porto, Portugal.
    Malva, Joao
    Univ Coimbra, Fac Med, IBILI, Coimbra, Portugal;Ageing Coimbra EIP AHA Reference Site, Coimbra, Portugal.
    Morais-Almeida, Mario
    CUF Descobertas Hosp, Allergy Ctr, Lisbon, Portugal.
    Pereira, Ana Margarida
    CUF Porto Hosp & Inst, Allergy Unit, Porto, Portugal;Univ Porto, CINTESIS, Ctr Res Hlth Technol & Informat Syst, Porto, Portugal.
    Todo-Bom, Ana
    Ctr Hosp Univ Coimbra, Imunoalergol, Coimbra, Portugal;Univ Coimbra, Fac Med, Coimbra, Portugal.
    Menditto, Enrica
    Univ Naples Federico II, CIRFF, Naples, Italy.
    Stellato, Cristiana
    Univ Salerno, Dept Med Surg & Dent, Scuola Med Salernitana, Salerno, Italy.
    Ventura, Maria Teresa
    Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Bari, Italy.
    Cruz, Alvaro A.
    Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil;WHO GARD Planning Grp, Salvador, BA, Brazil.
    Stelmach, Rafael
    Univ Sao Paulo, Fac Med, Hosp Clin, Heart Inst InCor,Pulm Div, Sao Paulo, Brazil.
    da Silva, Jane
    Univ Fed Santa Catarina, Dept Internal Med, Florianopolis, SC, Brazil;Univ Fed Santa Catarina, Allergy Clin, Florianopolis, SC, Brazil;Univ Fed Santa Catarina, Sao Thiago Univ Hosp, Florianopolis, SC, Brazil.
    Larenas-Linnemann, Desiree
    Hosp Med Sur, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico.
    Fuentes-Perez, Jose M.
    Hosp Gen Reg 1, Dr Carlos Mc Gregor Sanchez Navarro IMSS, Mexico City, DF, Mexico.
    Huerta-Villalobos, Yunuen R.
    Hosp Gen Reg 1, Dr Carlos Mc Gregor Sanchez Navarro IMSS, Mexico City, DF, Mexico.
    Emuzyte, Regina
    Vilnius Univ, Fac Med, Clin Childrens Dis, Vilnius, Lithuania.
    Kvedariene, Violeta
    Vilnius Univ, Fac Med, Vilnius, Lithuania.
    Valiulis, Arunas
    Vilnius Univ, Inst Clin Med, Clin Childrens Dis, Vilnius, Lithuania;Inst Hlth Sci, Dept Publ Hlth, Vilnius, Lithuania;EAP UEMS SP, Brussels, Belgium.
    Kuna, Piotr
    Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland.
    Samolinski, Boleslaw
    Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland.
    Klimek, Ludger
    Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg,Ctr Rhinol, Mannheim, Germany.
    Mosges, Ralph
    Univ Cologne, Fac Med, Inst Med Stat & Computat Biol, Cologne, Germany;CRI Clin Res Int, Hamburg, Germany.
    Pfaar, Oliver
    Phillipps Univ, Univ Hosp Marburg, Sect Rhinol & Allergy, Dept Otorhinolaryngol Head & Neck Surg, Marburg, Germany.
    Shamai, Sara
    Univ Cologne, Fac Med, Inst Med Stat & Computat Biol, Cologne, Germany;CRI Clin Res Int, Hamburg, Germany.
    Annesi-Maesano, Isabelle
    INSERM, Dept Inst Pierre Louis Epidemiol & Publ Hlth, Epidemiol Allerg & Resp Dis, Paris, France;UPMC Sorbonne Univ, Med Sch St Antoine, Paris, France.
    Bosse, Isabelle
    Demoly, Pascal
    Montpellier Univ Hosp, Dept Resp Dis, Montpellier, France.
    Fontaine, Jean-Francois
    Cardona, Vicky
    Hosp Valle De Hebron, Dept Internal Med, Allergy Sect, Barcelona, Spain;ARADyAL Res Network, Barcelona, Spain.
    Mullol, Joaquim
    Univ Barcelona, Hosp Clin, ENT Dept, Rhinol Unit, Barcelona, Spain;Univ Barcelona, Hosp Clin, ENT Dept, Smell Clin, Barcelona, Spain;Univ Barcelona, CIBERES, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain.
    Valero, Antonio
    Univ Barcelona, CIBERES, Pneumol & Allergy Dept, Barcelona, Spain;Univ Barcelona, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain.
    Roller-Wirnsberger, Regina E.
    Med Univ Graz, Dept Internal Med, Graz, Austria.
    Tomazic, Peter Valentin
    Med Univ Graz, Dept ENT, Graz, Austria.
    Chavannes, Niels H.
    Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands.
    Fokkens, Wytske J.
    Univ Amsterdam, Med Ctr, AMC, Dept Otorhinolaryngol, Amsterdam, Netherlands.
    Reitsma, Sietze
    Univ Amsterdam, Med Ctr, AMC, Dept Otorhinolaryngol, Amsterdam, Netherlands.
    Bewick, Mike
    iQ4U Consultants, London, England.
    Ryan, Dermot
    Univ Edinburgh, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland.
    Sheikh, Aziz
    Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.
    Haahtela, Tari
    Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland.
    Toppila-Salmi, Sanna
    Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland.
    Valovirta, Erkka
    Univ Turku, Dept Lung Dis & Clin Immunol, Turku, Finland;Terveystalo Allergy Clin, Turku, Finland.
    Makris, Michael
    Univ Athens, Attikon Univ Hosp, Dept Dermatol & Venereol 2, Allergy Unit D Kalogeromitros, Athens, Greece.
    Papadopoulos, Nikos G.
    Univ Manchester, Royal Manchester Childrens Hosp, Inst Human Dev, Ctr Pediat & Child Hlth, Manchester, Lancs, England;Univ Athens, Athens Gen Childrens Hosp P&A Kyriakou, Pediat Clin 2, UK Allergy Dept, Athens, Greece.
    Prokopakis, Emmanuel P.
    Univ Crete, Sch Med, Dept Otorhinolaryngol, Iraklion, Greece.
    Psarros, Fotis
    Athens Naval Hosp, Dept Allergy, Athens, Greece.
    Cingi, Cemal
    Eskisehir Osmangazi Univ, Fac Med, ENT Dept, Eskisehir, Turkey.
    Gemicioglu, Bilun
    Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Pulm Dis, Istanbul, Turkey.
    Yorgancioglu, Arzu
    Celal Bayar Univ, Fac Med, Dept Pulm Dis, Manisa, Turkey.
    Bosnic-Anticevich, Sinthia
    Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia;Woolcock Emphysema Ctr & Local Hlth Dist, Glebe, NSW, Australia.
    O'Hehir, Robyn E.
    Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia;Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia;Monash Univ, Dept Immunol, Melbourne, Vic, Australia;Univ S Florida, Div Allergy Immunol, Tampa, FL USA.
    Bachert, Claus
    Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium.
    Hellings, Peter W.
    Univ Hosp Leuven, Dept Otorhinolaryngol, Leuven, Belgium;Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands;Euforea, Brussels, Belgium.
    Pugin, Benoit
    European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium.
    Bindslev-Jensen, Carsten
    Odense Univ Hosp, ORCA, Dept Dermatol, Odense, Denmark;Odense Univ Hosp, ORCA, Allergy Ctr, Odense, Denmark.
    Eller, Esben
    Odense Univ Hosp, ORCA, Dept Dermatol, Odense, Denmark;Odense Univ Hosp, ORCA, Allergy Ctr, Odense, Denmark.
    Kull, Ingrid
    Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden;Sachs Children & Youth Hosp, Sodersjukhuset, Stockholm, Sweden.
    Melen, Erik
    Sachs Children & Youth Hosp, Sodersjukhuset, Stockholm, Sweden;Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
    Wickman, Magnus
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    De Vries, Gert
    Peercode BV, Geldermalsen, Netherlands.
    van Eerd, Michiel
    Peercode BV, Geldermalsen, Netherlands.
    Agache, Ioana
    Transylvania Univ Brasov, Brasov, Romania.
    Ansotegui, Ignacio J.
    Hosp Quiron Bizkaia, Dept Allergy & Immunol, Erandio, Spain.
    Dykewicz, Mark S.
    Hosp Quiron Bizkaia, Dept Allergy & Immunol, Erandio, Spain;St Louis Univ, Sch Med, Sect Allergy & Immunol, St Louis, MO USA.
    Casale, Thomas
    Wallace, Dana
    Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA.
    Waserman, Susan
    McMaster Univ, Dept Med Clin Immunol & Allergy, Hamilton, ON, Canada.
    Laune, Daniel
    INNOV, KYomed, Montpellier, France.
    Bousquet, Jean
    MACVIA France, Fdn Partenariale FMC VIA LR, Montpellier, France;Univ Hosp, Montpellier, France;Euforea, Brussels, Belgium;INSERM, U1168, VIMA Ageing & Chron Dis Epidemiol & Publ Hlth App, Villejuif, France;Univ Versailles St Quentin en Yvelines, Montigny Le Bretonneux, France.
    Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study2019Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 144, nr 1, s. 135-143Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H-1-antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H-1-antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible.

  • 8.
    Berthold, Malin
    et al.
    Thermo Fisher Sci, Uppsala, Sweden..
    Bjerg, Anders
    Univ Gothenburg, Krefting Res Ctr, Gothenburg, Sweden.;Obstruct Lung Dis Nothern Sweden OLIN Studies, Norrbotten Cty Council, Lulea, Sweden..
    Winberg, Anna
    Obstruct Lung Dis Nothern Sweden OLIN Studies, Norrbotten Cty Council, Lulea, Sweden.;Umea Univ Hosp, S-90185 Umea, Sweden..
    Mattsson, Lars
    Thermo Fisher Sci, Uppsala, Sweden..
    Borres, Magnus
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Pediatrik. Thermo Fisher Sci, Uppsala, Sweden..
    Ronmark, Eva
    Obstruct Lung Dis Nothern Sweden OLIN Studies, Norrbotten Cty Council, Lulea, Sweden.;Umea Univ, Dept Publ Hlth & Clin Med, OLIN Unit, Umea, Sweden..
    Association of Sensitization to Specific Pet Allergen Components with Asthma Symptoms in School Children2015Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 135, nr 2, s. AB22-AB22Artikkel i tidsskrift (Annet vitenskapelig)
  • 9. Bousquet, Jean
    et al.
    Hellings, Peter W
    Agache, Ioana
    Amat, Flore
    Annesi-Maesano, Isabella
    Ansotegui, Ignacio J
    Anto, Josep M
    Bachert, Claus
    Bateman, Eric D
    Bedbrook, Anna
    Bennoor, Kazi
    Bewick, Mickael
    Bindslev-Jensen, Carsten
    Bosnic-Anticevich, Sinthia
    Bosse, Isabelle
    Brozek, Jan
    Brussino, Luisa
    Canonica, Giorgio W
    Cardona, Victoria
    Casale, Thomas
    Cepeda Sarabia, Alfonso M
    Chavannes, Niels H
    Cecchi, Lorenzo
    Correia de Sousa, Jaime
    Costa, Elisio
    Cruz, Alvaro A
    Czarlewski, Wienczyslawa
    De Carlo, Giuseppe
    De Feo, Giulia
    Demoly, Pascal
    Devillier, Philippe
    Dykewicz, Mark S
    El-Gamal, Yehia
    Eller, Esben E
    Fonseca, Joao A
    Fontaine, Jean-François
    Fokkens, Wytske J
    Guzmán, Maria-Antonieta
    Haahtela, Tari
    Illario, Maddalena
    Ivancevich, Juan-Carlos
    Just, Jocelyne
    Kaidashev, Igor
    Khaitov, Musa
    Kalayci, Omer
    Keil, Thomas
    Klimek, Ludger
    Kowalski, Marek L
    Kuna, Piotr
    Kvedariene, Violeta
    Larenas-Linnemann, Desiree
    Laune, Daniel
    Le, Lan T T
    Carlsen, Karin Lodrup
    Lourenço, Olga
    Mahboub, Bassam
    Mair, Alpana
    Menditto, Enrica
    Milenkovic, Branislava
    Morais-Almeida, Mario
    Mösges, Ralph
    Mullol, Joaquim
    Murray, Ruth
    Naclerio, Robert
    Namazova-Baranova, Leyla
    Novellino, Ettore
    O'Hehir, Robyn E
    Ohta, Ken
    Okamoto, Yoshitaka
    Okubo, Kimi
    Onorato, Gabrielle L
    Palkonen, Susanna
    Panzner, Petr
    Papadopoulos, Nikos G
    Park, Hae-Sim
    Paulino, Ema
    Pawankar, Ruby
    Pfaar, Oliver
    Plavec, Davor
    Popov, Ted A
    Potter, Paul
    Prokopakis, Emmanuel P
    Rottem, Menachem
    Ryan, Dermot
    Salimäki, Johanna
    Samolinski, Boleslaw
    Sanchez-Borges, Mario
    Schunemann, Holger J
    Sheikh, Aziz
    Sisul, Juan-Carlos
    Rajabian-Söderlund, Rojin
    Sooronbaev, Talant
    Stellato, Cristiana
    To, Teresa
    Todo-Bom, Ana-Maria
    Tomazic, Peter-Valentin
    Toppila-Salmi, Sanna
    Valero, Antonio
    Valiulis, Arunas
    Valovirta, Erkka
    Ventura, Maria-Teresa
    Wagenmann, Martin
    Wang, De Yun
    Wallace, Dana
    Waserman, Susan
    Wickman, Magnus
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Yorgancioglu, Arzu
    Zhang, Luo
    Zhong, Nanshan
    Zidarn, Mihaela
    Zuberbier, Torsten
    Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology.2019Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 143, nr 3, s. 864-879Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional.

  • 10. Brandstrom, Josef
    et al.
    Borres, Magnus
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Pediatrik.
    Johansson, S. G. O.
    Roth, Agneta Jansson
    Sundqvist, Ann-Charlotte
    Lilja, Gunnar
    Nopp, Anna
    Nilsson, Caroline
    CD-Sens and Component Resolved Diagnostics In Diagnosing Hazelnut Allergy2014Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 133, nr 2, s. AB111-AB111Artikkel i tidsskrift (Annet vitenskapelig)
  • 11. Böhme, Maria
    et al.
    Kull, Inger
    Bergström, Anna
    Wickman, Magnus
    Nordvall, Lennart
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa.
    Pershagen, Goran
    Wahlgren, Carl-Fredrik
    Parental smoking increases the risk for eczema with sensitization in 4-year-old children2010Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 125, nr 4, s. 941-943Artikkel i tidsskrift (Fagfellevurdert)
  • 12.
    Carlson, Marie
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Håkansson, Lena
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Kämpe, Mary
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Stålenheim, Gunnemar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Peterson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Venge, Per
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Degranulation of eosinophils from pollen-atopic patients with asthma is increased during pollen season1992Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 89, nr 1 Pt 1, s. 131-139Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    The secretion of granule proteins from eosinophils and neutrophils was studied in isolated cells, obtained from 11 pollen-atopic patients with asthma, twice during and twice outside pollen season. Granulocytes were stimulated with serum-opsonized Sephadex particles, and the released amount of eosinophil cationic protein (ECP), eosinophil protein X (EPX), and myeloperoxidase (MPO) were measured by means of specific radioimmunoassay (RIA). Eosinophils from the pollen-atopic patients obtained during pollen season released significantly more (p less than 0.02) ECP and EPX than cells from the same patients obtained before pollen season. The released amount of ECP and EPX was correlated (r = 0.54; p less than 0.003) to the total pollen count. The release of MPO from neutrophils was only raised (p less than 0.01) at the end of the pollen season. Serum concentrations of ECP and EPX and blood eosinophil counts were significantly raised (p less than 0.002, p less than 0.001, and p less than 0.009, respectively) before pollen season and increased further at the end of the pollen season. There were no changes in lung function during pollen season and consequently no discernible relationships to eosinophil and neutrophil degranulation. We conclude that eosinophils and, to some extent, neutrophils from birch pollen-atopic subjects have an increased propensity to secrete their granule proteins during a pollen season. We suggest that these cells have been primed as a consequence of allergen exposure.

  • 13.
    Carlson, Marie
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Håkansson, Lena
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Peterson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Stålenheim, Gunnemar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Venge, Per
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Secretion of granule proteins from eosinophils and neutrophils is increased in asthma1991Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 87, nr 1 Pt 1, s. 27-33Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    The activity of eosinophil and neutrophil granulocytes with respect to secretion of granule proteins was studied in 30 patients with asthma and with varying severity of their disease. Granulocytes were stimulated with serum-opsonized Sephadex particles, and the released amount of eosinophil cationic protein (ECP), eosinophil protein X (EPX), and myeloperoxidase was measured by means of specific radioimmunoassays. Eosinophils from patients with asthma released significantly more (p less than 0.001) ECP and EPX after 20 minutes of incubation than cells from control subjects without asthma. The release of myeloperoxidase from neutrophils was also somewhat higher (p less than 0.03). The serum concentrations of ECP and EPX were also significantly increased (p less than 0.001) in the group with asthma. No significant relationships were found between clinical variables and the secretory activity of either eosinophils or neutrophils. We conclude that eosinophils and, to some extent, neutrophils from subjects with asthma have an increased propensity to release their granule proteins, which we suggest is a consequence of priming of these cells.

  • 14. Cazzoletti, Lucia
    et al.
    Marcon, Alessandro
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Corsico, Angelo
    Jarvis, Deborah
    Pin, Isabelle
    Accordini, Simone
    Almar, Enrique
    Bugiani, Massimiliano
    Carolei, Adriana
    Cerveri, Isa
    Duran-Tauleria, Enric
    Gislason, David
    Gulsvik, Amund
    Jõgi, Rain
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Marinoni, Alessandra
    Martínez-Moratalla, Jesús
    Vermeire, Paul
    de Marco, Roberto
    Asthma control in Europe: a real-world evaluation based on an international population-based study2007Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 120, nr 6, s. 1360-1367Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Epidemiologic evidence related to asthma control in   patients from the general population is scanty.

    Objectives: We sought to assess asthma control in several European   centers according to the Global Initiative for Asthma (GINA) guidelines   and to investigate its determinants.

    Methods: In the European Community Respiratory Health Survey 11   (1999-2002), 1241 adults with asthma were identified and classified   into inhaled corticosteroid (ICS) users and non-ICS users in the last   year. Control was assessed in both groups by using the GINA proposal   (controlled, partly controlled, and uncontrolled asthma), and it was   related to potential determinants.

    Results: Only 15% (95% CI, 12% to 19%) of subjects who had used ICSs in   the last year and 45% (95% CI, 41% to 50%) of non-ICS users had their   asthma under control; individuals with uncontrolled asthma accounted   for 49% (95% CI, 44% to 53%) and 18% (95% CI, 15% to 21%),   respectively. Among ICS users, the prevalence of uncontrolled asthma   showed great variability across Europe, ranging from 20% (95% CI, 7% to   41%; Iceland) to 67% (95% CI, 35% to 90%; Italy). Overweight status, chronic cough and phlegm, and sensitization to Cladosporium species   were associated with poor control in ICS users. About 65% and 87% of   ICS users with uncontrolled and partly controlled asthma, respectively,   were on a medication regimen that was less than recommended by the GINA   guidelines. Conclusion: Six of 7 European asthmatic adults using ICSs in the last   year did not achieve good disease control. The large majority of   subjects with poorly controlled asthma were using antiasthma drugs in a   suboptimal way. A wide variability in asthma control emerged across   Europe.

    Clinical implications: Greater attention should be paid to asthma management and to the implementation of the GINA guidelines.

  • 15. de Marco, Roberto
    et al.
    Marcon, Alessandro
    Jarvis, Deborah
    Accordini, Simone
    Bugiani, Massimiliano
    Cazzoletti, Lucia
    Cerveri, Isa
    Corsico, Angelo
    Gislason, David
    Gulsvik, Amund
    Jögi, Rain
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Martinez-Moratalla, J.
    Pin, Isabelle
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE2007Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 119, nr 3, s. 611-617Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: Few studies have investigated the long-term association between inhaled corticosteroids (ICSs) and lung function decline in asthma. OBJECTIVE: To evaluate whether prolonged treatment with ICSs is associated with FEV(1) decline in adults with asthma. METHODS: An international cohort of 667 subjects with asthma (20-44 years old) was identified in the European Community Respiratory Health Survey (1991-1993) and followed up from 1999 to 2002. Spirometry was performed on both occasions. FEV(1) decline was analyzed according to age, sex, height, body mass index, total IgE, time of ICS use, and smoking, while adjusting for potential confounders. RESULTS: As ICS use increased, the decline in FEV(1) was lower (P trend = .025): on average, decline passed from 34 mL/y in nonusers (half of the sample) to 20 mL/y in subjects treated for 48 months or more (18%). When adjusting for all covariates, there was an interaction (P = .02) between ICS use and total IgE: in subjects with high (>100 kU/L) IgE, ICS use for 4 years or more was associated with a lower FEV(1) decline (23 mL/y; 95% CI, 8-38 compared with nonusers). This association was not seen in those with lower IgE. CONCLUSION: Although confirming a beneficial long-term association between ICSs and lung function in asthma, our study suggests that subjects with high IgE could maximally benefit from a prolonged ICS treatment. CLINICAL IMPLICATIONS: This study adds further evidence to the beneficial effect of inhaled steroids on lung function in asthma; future studies will clarify whether calibrating the corticosteroid dose according to the level of total IgE is a feasible approach in asthma management.

  • 16.
    Dreborg, Sten
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Pediatrik.
    The risk of allergic reactions to allergen extracts in personnel2012Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 129, nr 3, s. 870-871Artikkel i tidsskrift (Fagfellevurdert)
  • 17.
    Ek, Weronica E
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Medicinsk genetik och genomik. Uppsala universitet, Science for Life Laboratory, SciLifeLab.
    Karlsson, Torgny
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Medicinsk genetik och genomik. Uppsala universitet, Science for Life Laboratory, SciLifeLab.
    Hernándes, Carlos Azuaje
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Medicinsk genetik och genomik. Uppsala universitet, Science for Life Laboratory, SciLifeLab.
    Rask-Andersen, Mathias
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Medicinsk genetik och genomik. Uppsala universitet, Science for Life Laboratory, SciLifeLab.
    Johansson, Åsa
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Medicinsk genetik och genomik. Uppsala universitet, Science for Life Laboratory, SciLifeLab.
    Breast-feeding and risk of asthma, hay fever, and eczema2018Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 141, nr 3, s. 1157-+Artikkel i tidsskrift (Annet vitenskapelig)
  • 18.
    Eriksson, Daniel
    et al.
    Karolinska Inst, Dept Med Solna, Ctr Mol Med, Stockholm, Sweden;Karolinska Univ Hosp, Dept Endocrinol Metab & Diabet, Stockholm, Sweden.
    Bacchetta, Rosa
    Stanford Univ, Dept Pediat, Sch Med, Div Stem Cell Transplantat & Regenerat Med, Stanford, CA 94305 USA.
    Gunnarsson, Hörður Ingi
    Karolinska Inst, Dept Med Solna, Ctr Mol Med, Stockholm, Sweden.
    Chan, Alice
    Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
    Barzaghi, Federica
    IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy, Pediat Immunohematol & Bone Marrow Transplantat U, Milan, Italy.
    Ehl, Stephan
    Univ Freiburg, Freiburg Univ Hosp, Ctr Chron Immunodeficiency, Fac Med, Freiburg, Germany.
    Hallgren, Åsa
    Karolinska Inst, Dept Med Solna, Ctr Mol Med, Stockholm, Sweden.
    van Gool, Frederic
    Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
    Sardh, Fabian
    Karolinska Inst, Dept Med Solna, Ctr Mol Med, Stockholm, Sweden.
    Lundqvist, Christina
    Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden.
    Laakso, Saila M.
    Univ Helsinki, Childrens Hosp, Helsinki, Finland;Helsinki Univ Hosp, Helsinki, Finland.
    Rönnblom, Anders
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Gastroenterologi/hepatologi.
    Ekwall, Olov
    Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden;Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Pediat, Gothenburg, Sweden.
    Mäkitie, Outi
    Univ Helsinki, Childrens Hosp, Helsinki, Finland;Helsinki Univ Hosp, Helsinki, Finland;Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden;Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden;Folkhalsan Inst Genet, Helsinki, Finland;Univ Helsinki, Helsinki, Finland.
    Bensing, Sophie
    Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
    Husebye, Eystein S.
    Karolinska Inst, Dept Med Solna, Ctr Mol Med, Stockholm, Sweden;Univ Bergen, Dept Clin Sci, Bergen, Norway;Haukeland Hosp, Dept Med, Bergen, Norway;KG Jebsen Ctr Autoimmune Disorders, Bergen, Norway.
    Anderson, Mark
    Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.
    Kämpe, Olle
    Karolinska Inst, Dept Med Solna, Ctr Mol Med, Stockholm, Sweden;Karolinska Univ Hosp, Dept Endocrinol Metab & Diabet, Stockholm, Sweden;KG Jebsen Ctr Autoimmune Disorders, Bergen, Norway.
    Landegren, Nils
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Autoimmunitet. Uppsala universitet, Science for Life Laboratory, SciLifeLab. Karolinska Inst, Dept Med Solna, Ctr Mol Med, Stockholm, Sweden.
    The autoimmune targets in IPEX are dominated by gut epithelial proteins2019Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 144, nr 1, s. 327-330Artikkel i tidsskrift (Annet vitenskapelig)
  • 19. Gendrin, Claire
    et al.
    Shubin, Nicholas J
    Boldenow, Erica
    Merillat, Sean
    Clauson, Morgan
    Power, Danial
    Doran, Kelly S
    Abrink, Magnus
    Pejler, Gunnar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinsk biokemi och mikrobiologi. Department of Anatomy, Physiology and Biochemistry, the Swedish University of Agricultural Sciences, Uppsala, Sweden.
    Rajagopal, Lakshmi
    Piliponsky, Adrian M
    Mast cell chymase decreases the severity of group B Streptococcus infections2018Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 142, nr 1, s. 120-129Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: Group B Streptococcus (GBS) or Streptococcus agalactiae are β-hemolytic gram-positive bacteria that colonize the lower genital tracts of women and are frequently associated with infections during pregnancy. Innate immune defenses are critical for controlling GBS dissemination and systemic infection. Mast cells are resident sentinel cells that come into contact with pathogens early during colonization and infection.

    OBJECTIVE: We aimed to investigate the contribution of chymase to systemic GBS infection and rates of preterm birth.

    METHODS: Pharmacologic and genetic approaches using mice deficient in mast cell protease (MCPT) 4, the mouse functional homologue of human chymase, were used.

    RESULTS: Our studies show that mast cells release a protease with chymotrypsin-like cleavage specificity in response to GBS. Additionally, increased GBS systemic infection and preterm births were observed in MCPT4-deficient mice versus MCPT4-sufficient mice. Furthermore, we observed that proteolytic cleavage of the host extracellular matrix protein fibronectin by peritoneal cell-derived mast cell lysates diminished GBS adherence. Consistent with this observation, the increase in GBS dissemination and preterm births observed in MCPT4-deficient mice was abolished when GBS was deficient in expression of the fibronectin-binding protein SfbA.

    CONCLUSIONS: Taken together, our results suggest that the protective effect of MCPT4 against GBS dissemination and preterm labor can be attributed in part to MCPT4-mediated proteolysis of fibronectin. Our studies reveal a novel role of mast cells in defense against bacterial infections.

  • 20.
    Guerrerio, Pamela A.
    et al.
    NIAID, LAD, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
    Rasooly, Marjohn
    NIAID, LAD, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
    Gu, Wenjuan
    Leidos Biomed Res Inc, bClin Res Directorate, Clin Monitoring Res Program, NCI Campus, Frederick, MD USA.
    Levin, Samara
    NIAID, LAD, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
    Jhamnani, Rekha
    NIAID, LAD, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
    Milner, Joshua D.
    NIAID, LAD, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
    Stone, Kelly D.
    NIAID, NIH, Lab Allerg Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA.
    Guerrerio, Anthony L.
    Johns Hopkins Univ, Baltimore, MD USA.
    Jones, Joseph
    Phadia US Inc, dImmuno Diagnost Branch, Thermo Fisher Sci, Portage, MI USA.
    Borres, Magnus P
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Forskargrupper (Inst. för kvinnor och barns hälsa), Pediatrisk inflammationsforskning. ThermoFisher Sci, Uppsala, Sweden.
    Brittain, Erica
    NIH, Biostat Res Branch, DCR, Bldg 10, Bethesda, MD 20892 USA.
    IgE Testing Can Predict Food Allergy Status in Patients with Moderate-Severe Atopic Dermatitis2019Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 143, nr 2, s. AB130-AB130, artikkel-id 392Artikkel i tidsskrift (Annet vitenskapelig)
  • 21. Gómez Real, Francisco
    et al.
    Svanes, Cecilie
    Omenaas, Ernst Reidar
    Antó, Josep Maria
    Plana, Estel
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Jarvis, Deborah
    Zemp, Elisabeth
    Wjst, Matthias
    Leynaert, B
    Sunyer, Jordi
    Menstrual irregularity and asthma and lung function2007Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 120, nr 3, s. 557-564Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Oligomenorrhea was associated with more asthma (Respiratory Health in Northern Europe study), but a possible association with lung function has not been investigated previously. Objective: To investigate whether oligomenorrhea was related to lung function and asthma, and whether body mass index and physical activity modified associations. Methods: Women age 28 to 44 years (n = 1631) participating in the European Community Respiratory Health Survey were included. Women who were taking exogenous sex hormones, were pregnant, or had recently given birth were excluded. Results: Long or irregular menstrual cycles were reported by 313 women (19%). Oligomenorrhea was significantly associated with more asthma symptoms (odds ratio [OR], 1.76; 95% CI, 1.29-2.40), allergic asthma (OR, 2.46; 95% CI, 1.43-4.23), and lower forced vital capacity (FVC; adjusted difference, 63 mL; 95% CI, -124 to -1). When excluding women using asthma medication, very lean women, or women exercising daily, these associations remained significant. Effects of oligomenorrhea were additive to those of body mass index (BMI) on asthma and FVC. Asthma symptoms increased significantly with BMI. FVC and FEV1 increased with BMI until 25 kg/m2 and thereafter decreased with increasing BMI. Excluding women exercising daily, asthma symptoms increased significantly with decreasing physical activity (OR, 1.09; 95% CI, 1.001-1.19) per category of physical activity) independently of oligomenorrhea. Among women exercising daily, oligomenorrhea predicted very high risk for asthma symptoms (OR, 12.6; 95% CI, 3.7-43). Conclusion: Women with oligomenorrhea have reduced lung function and more asthma, particularly allergic asthma, independent of BMI and physical activity. Airways pathology may have not only a hormonal but also a metabolic component. Clinical implications: Women with oligomenorrhea should be investigated with regard to asthma and lung function. Underlying metabolic disturbance should be considered in asthma.

  • 22. Hartmann, Karin
    et al.
    Escribano, Luis
    Grattan, Clive
    Brockow, Knut
    Carter, Melody C
    Alvarez-Twose, Ivan
    Matito, Almudena
    Broesby-Olsen, Sigurd
    Siebenhaar, Frank
    Lange, Magdalena
    Niedoszytko, Marek
    Castells, Mariana
    Oude Elberink, Joanna N G
    Bonadonna, Patrizia
    Zanotti, Roberta
    Hornick, Jason L
    Torrelo, Antonio
    Grabbe, Jürgen
    Rabenhorst, Anja
    Nedoszytko, Boguslaw
    Butterfield, Joseph H
    Gotlib, Jason
    Reiter, Andreas
    Radia, Deepti
    Hermine, Olivier
    Sotlar, Karl
    George, Tracy I
    Kristensen, Thomas K
    Kluin-Nelemans, Hanneke C
    Yavuz, Selim
    Hägglund, Hans
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Hematologi.
    Sperr, Wolfgang R
    Schwartz, Lawrence B
    Triggiani, Massimo
    Maurer, Marcus
    Nilsson, Gunnar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Hematologi.
    Horny, Hans-Peter
    Arock, Michel
    Orfao, Alberto
    Metcalfe, Dean D
    Akin, Cem
    Valent, Peter
    Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.2015Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Cutaneous lesions in patients with mastocytosis are highly heterogeneous and encompass localized and disseminated forms. Although a classification and criteria for cutaneous mastocytosis (CM) have been proposed, there remains a need to better define subforms of cutaneous manifestations in patients with mastocytosis. To address this unmet need, an international task force involving experts from different organizations (including the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology) met several times between 2010 and 2014 to discuss the classification and criteria for diagnosis of cutaneous manifestations in patients with mastocytosis. This article provides the major outcomes of these meetings and a proposal for a revised definition and criteria. In particular, we recommend that the typical maculopapular cutaneous lesions (urticaria pigmentosa) should be subdivided into 2 variants, namely a monomorphic variant with small maculopapular lesions, which is typically seen in adult patients, and a polymorphic variant with larger lesions of variable size and shape, which is typically seen in pediatric patients. Clinical observations suggest that the monomorphic variant, if it develops in children, often persists into adulthood, whereas the polymorphic variant may resolve around puberty. This delineation might have important prognostic implications, and its implementation in diagnostic algorithms and future mastocytosis classifications is recommended. Refinements are also suggested for the diagnostic criteria of CM, removal of telangiectasia macularis eruptiva perstans from the current classification of CM, and removal of the adjunct solitary from the term solitary mastocytoma.

  • 23. Heinrich, Joachim
    et al.
    Bedada, Getahun Bero
    Zock, Jan-Paul
    Chinn, Susan
    Norbäck, Dan
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Arbets- och miljömedicin.
    Olivieri, Mario
    Svanes, Cecilie
    Ponzio, Michela
    Verlato, Giuseppe
    Villani, Simona
    Jarvis, Deborah
    Luczynska, Christina
    Cat allergen level: its determinants and relationship to specific IgE to cat across European centers2006Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 118, nr 3, s. 674-681Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Cat allergen level in settled house dust and its determinants in Europe are unknown.

    Objective: The aim of this study is to quantify the level of cat allergens in mattress dust, to study its determinants, and to analyze the relationship with cat specific IgE on community level across European centers.

    Methods: Trained field workers collected dust from approximately 3000 mattresses during home visits in 22 European Community Respiratory Health Survey II centers. Sieved dust extracts were assayed for cat allergen using a mAb ELISA assay.

    Results: The overall geometric mean cat allergen was 0.94 mu g/g, ranging from 0.12 mu g/g in Huelva, Spain, to 3.76 mu g/g in Antwerp, Belgium. Current cat owners' homes showed substantially higher levels than past cat owners' and never cat owners' homes (geometric mean and 95% CI, 61.4 mu g/g [48.4-77.9] vs 1.37 mu g/g [0.97-1.9] vs 0.29 mu g/g [0.27-0.31]x). Community prevalence of cat ownership was moderately correlated with cat allergen levels in noncat owners (r(s) = 0.50), but not for past or current cat owners. The multilevel model identified community prevalence of cat keeping as the only statistically significant determinant of mattress cat allergen levels for noncat owners. However, averaged cat allergen levels per center were not related to community prevalence of detectable specific IgE to cat.

    Conclusion: Not having a cat in the home is associated with substantially lower Fel d 1 concentration, but does not protect against high Fel d 1 exposure in communities where cat ownership is common.

    Clinical implications: People (including patients with cat allergy) who do not own cats may be exposed to high levels of cat allergen in their home, particularly if they live in communities with high levels of cat ownership.

  • 24.
    Hohlfeld, Jens M.
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Schmiedl, Andreas
    Erpenbeck, Veit J.
    Venge, Per
    Krug, Norbert
    Eosinophil cationic protein alters pulmonary surfactant structure and function in asthma2004Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 113, nr 3, s. 496-502Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: Impaired surfactant function has been demonstrated in patients with asthma. Inhibitory proteins originating from plasma or inflammatory mediators are good candidates to contribute to this dysfunction. Eosinophils are potent effector cells in asthma, which, on activation, release inflammatory mediators, especially reactive granula proteins such as eosinophil cationic protein (ECP).

    OBJECTIVE: Because the potential role of ECP in the inhibition of surfactant function is not known, we tested the hypothesis of whether ECP levels in bronchoalveolar lavage fluid (BALF) of patients with asthma after segmental allergen provocation correlate to surfactant dysfunction. Furthermore, we tested the effect of purified ECP on surfactant function and structure in vitro.

    METHODS: Surfactant isolated from BALF of asthmatic patients was assessed for biophysical function with the Pulsating Bubble Surfactometer and the Capillary Surfactometer and correlated to ECP levels. Purified ECP and plasma proteins at various concentrations were incubated with natural surfactant. Surfactant function was studied with the Capillary Surfactometer, and surfactant structure was determined by electron microscopy.

    RESULTS: ECP is elevated in BALF from patients with asthma after allergen challenge compared with baseline. ECP levels after allergen challenge correlate well to surfactant dysfunction. In vitro, ECP induces a concentration-dependent inhibition of surfactant function that can be inhibited by antibodies against ECP. ECP is more potent compared with albumin or fibrinogen. Finally, ECP induces severe ultrastructural changes to surfactant vesicles that are more pronounced than changes induced by either fibrinogen or albumin.

    CONCLUSIONS: ECP contributes to surfactant dysfunction in asthma, which in turn could lead to airway obstruction.

  • 25.
    Håkansson, L
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Carlson, M
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Stålenheim, G
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Venge, P
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Migratory responses of eosinophil and neutrophil granulocytes from patients with asthma1990Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 85, nr 4, s. 743-750Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    In the present study the migratory function of eosinophil and neutrophil granulocytes from patients with asthma were investigated. Fifty-seven patients with asthmatic disease of varying severity were included. Eosinophil and neutrophil chemotactic responses to 5% pooled normal human serum (NHS), 5% allergen-challenge serum, 2.5% zymosan-activated serum, N-formyl-methionyl-leucyl-phenylalanine (10 nmol/L), chemokinetic responses to albumin (2 gm/L) and 5% NHS, and the eosinophil and neutrophil chemotactic and chemokinetic activities of serum were investigated. Eosinophils from patients with asthma demonstrated significantly (p less than 0.02) increased chemotactic responses to allergen-challenge serum, zymosan-activated serum, and N-formyl-methionyl-leucyl-phenylalanine, compared with eosinophils from references. The chemokinetic responses to albumin and NHS were increased (p less than 0.01) by eosinophils from the patients who had blood eosinophilia (greater than 400 X 10(6)/L). Sera from the patients with asthma demonstrated raised eosinophil chemotactic activity (p less than 0.001) and raised eosinophil and neutrophil chemokinetic activity (p less than 0.001). The eosinophil chemokinetic activity of serum was correlated to the relative peak expiratory flow rate of the patients (r = -0.43; p less than 0.02). The increased migratory responses were specific for the eosinophils, since the migratory responses of their neutrophils were not altered compared with that of the references. These results suggest that the eosinophils from the patients with asthma had been exposed to a priming mechanism in vivo.

  • 26.
    Håkansson, Lena
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Heinrich, Christina
    Rak, Sabina
    Venge, Per
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy1997Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 99, nr 4, s. 551-562Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    The adhesion of eosinophil granulocytes to E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) was investigated before and during birch pollen season in 24 patients allergic to birch pollen who had rhinoconjunctivitis and, in half of the cases, asthma during season. Half of the patients were undergoing specific immunotherapy for birch pollen allergy. Increased adhesion to VCAM-1 and ICAM-1 (p < 0.05) during season as compared with before season was demonstrated by eosinophils of patients in the control group and by eosinophils of the patients without asthma treated with immunotherapy, but not by eosinophils from the immunotherapy-treated patients with asthma. Eosinophils from the control group of patients demonstrated increased cell surface expression of CD18 and CD49d (p < 0.05 and p < 0.01, respectively) during season as compared with before season, and eosinophils from the immunotherapy-treated patients showed increased cell surface expression of CD49d (p < 0.01) during season. Simultaneous measurement of neutrophil adhesion revealed increased adhesion to E-selectin and ICAM-1 (p < 0.01) during season compared with before season in the immunotherapy-treated group of patients. Neutrophils from the control subjects without asthma showed increased adhesion to E-selectin (p < 0.05) during season. In conclusion, eosinophils from patients allergic to birch pollen demonstrated priming of the adhesion to VCAM-1 to ICAM-1 during birch pollen season. Immunotherapy treatment prevented the priming of eosinophil adhesion during pollen season in the patients allergic to birch pollen who had asthma, but not in those without asthma. In contrast, neutrophils from the immunotherapy-treated patients, both with and without asthma, demonstrated priming of the adhesion to E-selectin and ICAM-1 during season. The latter results indicate that immunotherapy, in case of the patients allergic to birch pollen with asthma induced a shift from the production of primarily eosinophil priming agents to primarily neutrophil priming agents, which may be caused by a shift from Th2 to Th1 lymphocytes.

  • 27.
    Ingelsson, Erik
    et al.
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet.
    Yin, Li
    Bäck, Magnus
    Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease2012Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 129, nr 3, s. 702-707.e2Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: The leukotriene pathway has been associated with an increased cardiovascular risk. However, the effects of the antileukotriene treatment used in asthmatic patients on cardiovascular outcomes have remained largely unexplored.

    OBJECTIVE: We sought to examine a potential protective role of the leukotriene receptor antagonist montelukast on future risk of incident and recurrent myocardial infarction and ischemic stroke.

    METHODS: A nationwide population-based cohort of approximately 7 million persons integrating data from the Prescribed Drug, Patient, Cause of Death, Income, Educational, and Emigration Registers was followed from July 1, 2005, to December 31, 2008. Analyses were performed in the whole population after exclusion of subjects with a prior cardiovascular diagnosis (incident events; sample size, n = 6,910,923 for myocardial infarction and n = 6,932,578 for stroke) and in subjects with a prior diagnosis (recurrent events; n = 153,937 and n = 132,291 for stroke and myocardial infarction, respectively).

    RESULTS: Cox proportional hazard ratios (HRs) did not reveal an association of montelukast use with incident events. In contrast to these findings, montelukast use was associated with a lower risk for recurrent stroke (HR, 0.62; 95% CI, 0.38-0.99) accounting for age, sex, education level, and yearly income. Adjusting the latter finding also for respiratory and cardiovascular medications and diagnoses revealed similar point estimates (HR, 0.62; 95% CI, 0.39-1.0). Post hoc analyses revealed a significant association of montelukast use with a lower risk for recurrent myocardial infarction in male subjects (HR, 0.65; 95% CI, 0.43-0.99).

    CONCLUSION: These data provide a first indication for a potential role of the antiasthma drug montelukast for secondary prevention of cardiovascular disease.

  • 28. Ito, Komei
    et al.
    Sjölander, Sigrid
    Sato, Sakura
    Movérare, Robert
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Tanaka, Akira
    Soderstrom, Lars
    Borres, Magnus
    Poorafshar, Maryam
    Ebisawa, Motohiro
    IgE to Gly m 5 and Gly m 6 is associated with severe allergic reactions to soybean in Japanese children2011Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 128, nr 3, s. 673-675Artikkel i tidsskrift (Fagfellevurdert)
  • 29.
    Janson, Christer
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Asbjornsdottir, Hulda
    Birgisdottir, Alda
    Sigurjonsdottir, R B
    Gunnbjörnsdottir, María
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Gislason, D
    Olafsson, Isleifur
    Cook, E
    Jögi, Rain
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Gislason, Thorarinn
    Thjodleifsson, Bjarni
    The effect of infectious burden on the prevalence of atopy and respiratory allergies in Iceland, Estonia, and Sweden2007Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 120, nr 3, s. 673-679Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Epidemiologic reports on the effect of microbe exposure on the development of atopy and allergic asthma are inconsistent. Objectives: The study investigates the association between serologic markers of infections and occurrence of atopy, allergic asthma, and rhinitis among adults in Iceland, Sweden, and Estonia. Methods: Individuals (n = 1249; mean age, 42 years) from Iceland, Sweden, and Estonia underwent a structured interview and blood sampling. Specific IgE was measured against 4 allergens, and IgG antibodies were measured against Helicobacter pylori, Toxoplasmosis gondii, hepatitis A virus, herpes simplex virus 1, Chlamydia pneumoniae, EBV, and cytomegalovirus. Results: Nonatopic subjects more often had positive serology for Helicobacter pylori, herpes simplex virus 1, Chlamydia pneumoniae, and cytomegalovirus. Having a low number (≤3) of IgG antibodies against the various infectious agents was an independent risk factor for atopy (odds ratio [OR], 1.43; 95% CI, 1.06-1.93), allergic asthma (OR, 1.82; 95% CI, 1.12-2.98), and allergic rhinitis (OR, 1.69; 95% CI, 1.21-2.37). The proportion of atopy that can be explained by a lower number (≤3) of infections was 6.7% in Iceland, 9.2% in Estonia, and 16.4% in Sweden, and 6.7%, 48.2%, and 33.4% for allergic asthma, respectively. Conclusion: Our data are consistent with cumulative protective effect of infections against atopy and respiratory allergies irrespective of route of infection. Clinical implications: The study indicates what microbes or combination of microbes play a role in the complex interplay between hygiene and allergy and may contribute toward the understanding of the allergy epidemic.Background: Epidemiologic reports on the effect of microbe exposure on the development of atopy and allergic asthma are inconsistent. Objectives: The study investigates the association between serologic markers of infections and occurrence of atopy, allergic asthma, and rhinitis among adults in Iceland, Sweden, and Estonia. Methods: Individuals (n = 1249; mean age, 42 years) from Iceland, Sweden, and Estonia underwent a structured interview and blood sampling. Specific IgE was measured against 4 allergens, and IgG antibodies were measured against Helicobacter pylori, Toxoplasmosis gondii, hepatitis A virus, herpes simplex virus 1, Chlamydia pneumoniae, EBV, and cytomegalovirus. Results: Nonatopic subjects more often had positive serology for Helicobacter pylori, herpes simplex virus 1, Chlamydia pneumoniae, and cytomegalovirus. Having a low number (≤3) of IgG antibodies against the various infectious agents was an independent risk factor for atopy (odds ratio [OR], 1.43; 95% CI, 1.06-1.93), allergic asthma (OR, 1.82; 95% CI, 1.12-2.98), and allergic rhinitis (OR, 1.69; 95% CI, 1.21-2.37). The proportion of atopy that can be explained by a lower number (≤3) of infections was 6.7% in Iceland, 9.2% in Estonia, and 16.4% in Sweden, and 6.7%, 48.2%, and 33.4% for allergic asthma, respectively. Conclusion: Our data are consistent with cumulative protective effect of infections against atopy and respiratory allergies irrespective of route of infection. Clinical implications: The study indicates what microbes or combination of microbes play a role in the complex interplay between hygiene and allergy and may contribute toward the understanding of the allergy epidemic.

  • 30. Jarvis, Deborah
    et al.
    Zock, Jan-Paul
    Heinrich, Joachim
    Svanes, Cecilie
    Verlato, Giuseppe
    Olivieri, Mario
    Villani, Simona
    Ponzio, Michela
    Leynaert, Benedicte
    Sunyer, Jordi
    Dahlman-Höglund, Anna
    Chinn, Susan
    Luczynska, Christina
    Norbäck, Dan
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Arbets- och miljömedicin.
    Burney, Peter
    Cat and dust mite allergen levels, specific IgG and IgG4, and respiratory symptoms in adults2007Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 119, nr 3, s. 697-704Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Exposure to allergen may induce a modified TH2 response characterized by high IgG4 levels, absence of IgE sensitization, and a decreased risk of allergic respiratory symptoms. Objective: To assess the association of IgG4 level with allergic respiratory symptoms in a community-based sample of adults. Methods: Information on exposure to cats, respiratory symptoms, and mattress allergen levels was obtained from 2780 adults. Levels of cat and house dust mite (HDM) specific IgE, IgG, and IgG4 were measured. The association of exposure to allergen with IgG4 and of IgG4 with symptoms was assessed. Results: Geometric mean (GM) cat specific IgG and IgG4 was higher in subjects who had a cat that was allowed in the bedroom than in subjects without a cat (adjusted ratio of GM IgG4, 1.41; 95% CI, 1.25-1.57). Levels of HDM specific IgG and IgG4 were similar in subjects with undetectable and high (>20.22 μg/g) mattress Der 1 levels (adjusted ratio of GM IgG4, 1.02; 95% CI, 0.89-1.17). There was no evidence that high cat or HDM specific IgG4 levels were associated with less IgE sensitization or with fewer symptoms. Conclusion: In this community-based sample of adults, high IgG4 levels to cat or HDM were not associated with a lower risk of allergic respiratory symptoms. Clinical implications: In adults, high cat allergen exposure does not protect against respiratory symptoms.

  • 31.
    Konradsen, Jon R.
    et al.
    Karolinska Inst, Stockholm, Sweden..
    Nordlund, Bjorn
    Karolinska Inst, Bromma, Sweden..
    Ohrmalm, Lars
    Karolinska Inst, Stockholm, Sweden..
    Broliden, Kristina
    Karolinska Inst, Stockholm, Sweden..
    Alving, Kjell
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Forskargrupper (Inst. för kvinnor och barns hälsa), Pediatrisk inflammationsforskning.
    Hedlin, Gunilla
    Karolinska Inst, Stockholm, Sweden..
    Microbiological findings in children with severe asthma2018Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 141, nr 2, s. AB99-AB99Artikkel i tidsskrift (Annet vitenskapelig)
  • 32.
    Käck, Ulrika
    et al.
    Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, S1,Sjukhusbacken 10, S-11883 Stockholm, Sweden.
    Asarnoj, Anna
    Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden;Karolinska Inst, Dept Med, Solna Immunol & Allergy Unit, Stockholm, Sweden;Karolinska Univ Hosp, Stockholm, Sweden.
    Grönlund, Hans
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
    Borres, Magnus P
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Forskargrupper (Inst. för kvinnor och barns hälsa), Pediatrisk inflammationsforskning. Thermo Fisher Sci, Uppsala, Sweden.
    van Hage, Marianne
    Karolinska Inst, Dept Med, Solna Immunol & Allergy Unit, Stockholm, Sweden;Karolinska Univ Hosp, Stockholm, Sweden.
    Lilja, Gunnar
    Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, S1,Sjukhusbacken 10, S-11883 Stockholm, Sweden.
    Konradsen, Jon R.
    Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden;Karolinska Inst, Dept Med, Solna Immunol & Allergy Unit, Stockholm, Sweden;Karolinska Univ Hosp, Stockholm, Sweden.
    Molecular allergy diagnostics refine characterization of children sensitized to dog dander2018Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 142, nr 4, s. 1113-+Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Sensitization to dog dander is an important risk factor for rhinoconjunctivitis and asthma but is not sufficient for diagnosing dog allergy. Molecular allergy diagnostics offer new opportunities for refined characterization. Objectives: We sought to study the association between sensitization to all presently known dog allergen components and clinical symptoms of dog allergy in children evaluated by using nasal provocation tests (NPTs). Methods: Sixty children (age, 10-18 years) sensitized to dog dander extract underwent NPTs with dog dander extract. Measurement of IgE levels to dog dander and to Can f 1, Can f 2, Can f 3, and Can f 5 was performed with ImmunoCAP, and measurement of IgE levels to Can f 4 and Can f 6 was performed with streptavidin ImmunoCAP. An IgE level of 0.1 kU(A)/L or greater was considered positive. Results: There was an association between sensitization to an increasing number of dog allergen components and a positive nasal challenge result (P = .01). Sensitization to lipocalins (odds ratio [OR], 6.0; 95% CI, 1.04-34.5), in particular Can f 4 (OR, 6.80; 95% CI 1.84-25.2) and Can f 6 (OR, 5.69; 95% CI, 1.59-20.8), was associated with a positive NPT result. Monosensitization to Can f 5 was related to a negative NPT result (OR, 5.78; 95% CI, 1.01-33.0). Conclusion: Sensitization to an increasing number of dog allergen components and to lipocalins is associated with dog allergy. Monosensitization to Can f 5 should not be regarded primarily as a marker for dog allergy.

  • 33.
    Käck, Ulrika
    et al.
    Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden.
    Asarnoj, Anna
    Karolinska Inst, Dept Med Solna, Immunol & Allergy Unit, Stockholm, Sweden;Karolinska Univ Hosp, Stockholm, Sweden;Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.
    Grönlund, Hans
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
    Borres, Magnus P
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Forskargrupper (Inst. för kvinnor och barns hälsa), Pediatrisk inflammationsforskning. ThermoFisher Sci, Uppsala, Sweden.
    van Hage, Marianne
    Karolinska Inst, Dept Med Solna, Immunol & Allergy Unit, Stockholm, Sweden;Karolinska Univ Hosp, Stockholm, Sweden.
    Lilja, Gunnar
    Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden.
    Konradsen, Jon R.
    Karolinska Inst, Dept Med Solna, Immunol & Allergy Unit, Stockholm, Sweden;Karolinska Univ Hosp, Stockholm, Sweden;Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.
    Reply to: Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it2019Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 143, nr 4, s. 1658-1659Artikkel i tidsskrift (Fagfellevurdert)
  • 34. Laitinen, Lauri A.
    et al.
    Laitinen, Annika
    Altraja, Alan
    Virtanen, Ismo
    Kämpe, Mary
    Simonsson, Bo G.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Karlsson, Sven-Erik
    Håkansson, Lena
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Venge, Per
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper.
    Sillastu, Heinart
    Bronchial biopsy findings in intermittent or "early" asthma1996Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 98, nr 5 Pt 2, s. S3-6, discussion S33-40Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Bronchial biopsy specimens from subjects with intermittent or "early" asthma were compared with specimens taken from healthy subjects. Patients with early asthma included those with seasonal asthma and occupational asthma. There was a small but statistically significant increase in the thickness of the subepithelial extracellular matrix protein tenascin in subjects with seasonal and occupational asthma compared with control subjects. Collagen types IV and VII were increased only in patients with occupational asthma. Eosinophils were the only inflammatory cells that were significantly increased in subjects with seasonal asthma compared with control subjects. These data show that inflammation is present in the airways of patients with early asthma, and the increase in tenascin expression in the basement membrane zone suggests that structural changes are also initiated at an early stage of the disease.

  • 35. Levänen, Bettina
    et al.
    Bhakta, Nirav R
    Torregrosa Paredes, Patricia
    Barbeau, Rebecca
    Hiltbrunner, Stefanie
    Pollack, Joshua L
    Sköld, C Magnus
    Svartengren, Magnus
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Arbets- och miljömedicin.
    Grunewald, Johan
    Gabrielsson, Susanne
    Eklund, Anders
    Larsson, Britt-Marie
    Woodruff, Prescott G
    Erle, David J
    Wheelock, Åsa M
    Altered microRNA profiles in bronchoalveolar lavage fluid exosomes in asthmatic patients.2013Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 131, nr 3, s. 894-903Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: Asthma is characterized by increased airway narrowing in response to nonspecific stimuli. The disorder is influenced by both environmental and genetic factors. Exosomes are nanosized vesicles of endosomal origin released from inflammatory and epithelial cells that have been implicated in asthma. In this study we characterized the microRNA (miRNA) content of exosomes in healthy control subjects and patients with mild intermittent asthma both at unprovoked baseline and in response to environmental challenge.

    OBJECTIVE: To investigate alterations in bronchoalveolar lavage fluid (BALF) exosomal miRNA profiles due to asthma, and following subway air exposure.

    METHODS: Exosomes were isolated from BALF from healthy control subjects (n = 10) and patients with mild intermittent asthma (n = 10) after subway and control exposures. Exosomal RNA was analyzed by using microarrays containing probes for 894 human miRNAs, and selected findings were validated with quantitative RT-PCR. Results were analyzed by using multivariate modeling.

    RESULTS: The presence of miRNAs was confirmed in exosomes from BALF of both asthmatic patients and healthy control subjects. Significant differences in BALF exosomal miRNA was detected for 24 miRNAs with a subset of 16 miRNAs, including members of the let-7 and miRNA-200 families, providing robust classification of patients with mild nonsymptomatic asthma from healthy subjects with 72% cross-validated predictive power (Q(2) = 0.72). In contrast, subway exposure did not cause any significant alterations in miRNA profiles.

    CONCLUSION: These studies demonstrate substantial differences in exosomal miRNA profiles between healthy subjects and patients with unprovoked, mild, stable asthma. These changes might be important in the inflammatory response leading to bronchial hyperresponsiveness and asthma.

  • 36. Lindvik, Helene
    et al.
    Mowinckel, Petter
    Navaratnam, Jesintha
    Carlsen, Karin Cecilie Lodrup
    Borres, Magnus
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Pediatrik.
    Kvenshagen, Bente
    Carlsen, Kai Hakon
    Does Peanut Allergen Conjunctival Provocation Test Reflect Specific IgE Levels To Peanut?2014Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 133, nr 2, s. AB110-AB110Artikkel i tidsskrift (Annet vitenskapelig)
  • 37. Macsali, Ferenc
    et al.
    Real, Francisco Gómez
    Omenaas, Ernst Reidar
    Bjorge, Line
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Franklin, Karl
    Svanes, Cecilie
    Oral contraception, body mass index, and asthma: a cross-sectional Nordic-Baltic population survey2009Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 123, nr 2, s. 391-397Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: Emerging evidence suggests that sex steroid hormones may influence airways obstruction, and that metabolic status may modify potential effects. OBJECTIVE: This study investigated the association between use of oral contraceptive pills (OCPs) and asthma in a Nordic-Baltic population-based study, while taking into account possible interplay with body mass index (BMI). METHODS: Postal questionnaires were sent to subjects in Denmark, Estonia, Iceland, Norway, and Sweden from 1999 to 2001 (response rate in women, 77%). Pregnant women, women using hormone replacement therapy, and women >45 years were excluded. Analyses included 5791 women 25 to 44 years old, of whom 961 (17%) used OCP. Logistic regression analyses included adjustment for smoking, irregular menstruation, BMI, age, type of dwelling, and center. RESULTS: Oral contraceptive pills were associated with increased risk for asthma (odds ratio, 1.42; 95% CI, 1.09-1.86), asthma with hay fever (1.48; 1.08-2.03), wheeze with shortness of breath (1.27; 1.02-1.60), hay fever (1.25; 1.06-1.48), and >/=3 asthma symptoms (1.29; 1.05-1.58). The findings were consistent between centers. The associations were present only among normal weight women (BMI 20-25 kg/m(2), asthma: 1.45; 1.02-2.05) and overweight women (BMI >25kg/m(2): 1.91; 1.20-3.02), but not among lean women (BMI <20 kg/m(2): 0.41; 0.12-1.40). Interaction between BMI and OCP in association with asthma was significant (P(interaction) < .05). CONCLUSIONS: Women using oral contraceptive pills had more asthma. This was found only in normal weight and overweight women, indicating interplay between sex hormones and metabolic status in effect on the airways. The findings originate from a cross-sectional postal survey and should be interpreted with caution; it is recommended that asthma symptoms are included in clinical trials of oral contraception.

  • 38.
    Magnusson, Jessica
    et al.
    Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
    Ekstrom, Sandra
    Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
    Kull, Inger
    Karolinska Inst, Inst Environm Med, Stockholm, Sweden;South Gen Hosp, Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden;Karolinska Inst, Dept Educ & Clin Sci, Stockholm, Sweden.
    Håkansson, Niclas
    Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
    Nilsson, Sara
    Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden;Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
    Wickman, Magnus
    Karolinska Inst, Inst Environm Med, Stockholm, Sweden;South Gen Hosp, Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden.
    Melen, Erik
    Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden;Karolinska Inst, Inst Environm Med, Stockholm, Sweden;South Gen Hosp, Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden.
    Risérus, Ulf
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för folkhälso- och vårdvetenskap, Klinisk nutrition och metabolism.
    Bergström, Anna
    Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden;Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
    Polyunsaturated fatty acids in plasma at 8 years and subsequent allergic disease2018Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 142, nr 2, s. 510-516Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Polyunsaturated fatty acids (PUFAs) are hypothesized to modulate the risk of allergic disease. However, evidence from previous studies is inconclusive, and limited longitudinal data exist using circulating biomarkers of PUFA intake and metabolism. Objective: We aimed to investigate associations between n-3 and n-6 PUFAs at age 8 years and asthma, rhinitis, and aeroallergen sensitization at age 16 years. Methods: Proportions of n-3 PUFAs (very long-chain n-3 [VLC n-3; sum of eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid] anda-linolenic acid) and n-6PUFAs (linoleic acid and arachidonic acid [AA]) in blood samples at age 8 years weremeasured for 940 children fromthe prospective Swedish birth cohort BAMSE (Children, Allergy, Milieu, Stockholm, Epidemiology). Allergic disease phenotypes were defined by using questionnaires and IgE measures at the ages of 8 and 16 years. Logistic regression was used to examine potential associations. Results: A higher proportion of total VLC n-3 PUFAs in plasma at age 8 years was associated with a reduced risk of prevalent asthma, rhinitis, and aeroallergen sensitization at age 16 years and with incidence of asthma between 8 and 16 years (adjusted odds ratio, 0.67; 95% CI, 0.47-0.94). AA was associated with a reduced risk of asthma, aeroallergen sensitization, and allergic rhinitis. The findings were most evident for allergic phenotypes of asthma and rhinitis. Additionally, AA was associated with an increased probability of asthma and rhinitis remission between 8 and 16 years of age. Conclusion: Higher proportions of certain VLC n-3 and very long-chain n-6 PUFAs in plasma phospholipids at age 8 years were associated with a reduced risk of allergic disease at age 16 years.

  • 39.
    Malinovschi, Andrei
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Klinisk fysiologi.
    Fonseca, Joao A.
    Jacinto, Tiago
    Alving, Kjell
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Pediatrik.
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects2013Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 132, nr 4, s. 821-+Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Fraction of exhaled nitric oxide (FENO) and blood eosinophil count (B-Eos) values, markers of local and systemic eosinophilic inflammation, respectively, are increased in asthmatic patients. Little is known about the relation of these markers to reportedwheeze and asthma events in a random population sample. Objectives: We sought to determine the individual and independent values of B-Eos and FENO in relation to wheeze, asthma diagnosis, and asthma events in a cross-sectional study. Methods: FENO and B-Eos values were measured in 12,408 subjects aged 6 to 80 years from the National Health and Nutrition Examination Survey 2007-2008 and 2009-2010. Current wheeze and asthma diagnosis, as well as asthma attacks and asthma-related emergency department (ED) visits within the last 12 months, were assessed by means of questionnaires. Results: Intermediate or high FENO values and intermediate or high B-Eos values were independently associated with having asthma, wheeze, and asthma attacks. However, only intermediate and high B-Eos values were independently associated with asthma-related ED visits. High FENO (>= 50 ppb) and B-Eos (>= 500 cells/ mm(3)) values rendered an adjusted odds ratio of 4.5 of having wheeze, 5.1 of having asthma, 5.4 for asthma attacks, and 2.9 for asthma-related ED visits compared with normal FENO (< 25 ppb) and B-Eos (< 300 cells/ mm(3)) values. Conclusions: Exhaled nitric oxide and B-Eos values offered independent information in relation to the prevalence of wheeze, asthma diagnosis, and asthma events in this random population sample. The clinical importance of these findings in asthmatic patients with regard to phenotyping and individualized treatment, considering both local and systemic eosinophilic inflammation, needs to be determined.

  • 40.
    Malinovschi, Andrei
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Klinisk fysiologi.
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Borres, Magnus P
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Pediatrik.
    Alving, Kjell
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa.
    Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity2016Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 138, nr 5, s. 1301-1308Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: We have previously described that fraction of exhaled nitric oxide (Feno) levels and blood eosinophil counts offer additive information in relation to asthma and asthma exacerbations when analyzing data from a large population study.

    OBJECTIVE: We sought to investigate increased Feno levels and blood eosinophil counts in relation to lung function, bronchial hyperresponsiveness (BHR), and asthma control in a cohort of young asthmatic patients.

    METHODS: Measurements of Feno levels and blood eosinophil counts were available in 406 subjects (208 women) aged 10 to 35 years. Asthma control was assessed through the Asthma Control Test. Moderate-to-severe BHR was defined as a cumulative dose of methacholine of less than 0.3 mg causing an FEV1 decrease of 20%.

    RESULTS: Subjects with simultaneously increased Feno levels (≥20-25 ppb) and blood eosinophil counts (≥0.3 × 10(9)/L) had a higher prevalence of uncontrolled asthma (Asthma Control Test score, <20) than subjects with singly increased blood eosinophil counts (40.5% vs 21.1%, P = .01). This difference remained significant (P = .006), and a significant difference was also found between subjects with both increased Feno levels and blood eosinophil counts and subjects with normal Feno levels and blood eosinophil counts (P = .02) after adjusting for confounders. Having increased Feno levels and blood eosinophil counts related to a higher prevalence of moderate-to-severe BHR than having normal Feno levels and blood eosinophil counts or singly increased Feno levels or blood eosinophil counts (85.7% vs 35.8% or 63.3% or 60%, P < .05 all comparisons).

    CONCLUSION: We have shown that simultaneously increased local (Feno) and systemic (blood eosinophil) markers of type 2 inflammation related to a higher likelihood of BHR and uncontrolled asthma in a large cohort of young asthmatic patients.

  • 41. Marcon, Alessandro
    et al.
    Cerveri, Isa
    Wjst, Matthias
    Anto, Josep
    Heinrich, Joachim
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Jarvis, Deborah
    Leynaert, Benedicte
    Probst-Hensch, Nicole
    Svanes, Cecilie
    Toren, Kjell
    Burney, Peter
    de Marco, Roberto
    Can an airway challenge test predict respiratory diseases?: A population-based international study2014Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 133, nr 1, s. 104-+Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Evidence on the longitudinal association of airway responsiveness with respiratory diseases is scarce. The best indicator of responsiveness is still undetermined. Objective: We investigated the association of airway responsiveness with the incidence of asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Methods: We studied 3851 subjects who underwent spirometry and methacholine challenge tests both at baseline (1991-1993), when they were 20 to 44 years old, and at follow-up (1999-2002) in the European Community Respiratory Health Survey. Airway responsiveness was defined based on the methacholine dose-response slope on both occasions. Incidence rate ratios for the association of airway responsiveness with disease occurrence were computed by using Poisson regression. Results: With respect to reference (slope of the fourth quintile or greater), subjects with the greatest degree of airway responsiveness (slope less than the first quintile) showed the greatest risk of developing asthma, COPD, and allergic rhinitis (incidence rate ratios of 10.82, 5.53, and 4.84, respectively; all P < .01). A low slope predicted disease occurrence, even in subjects who did not reach a 20% decrease in FEV1 at the cumulative dose of 1 mg of methacholine (PD20 > 1 mg). A decrease in slope over time was an independent predictor of disease risk. Conclusion: Airway responsiveness predicted new-onset asthma, COPD, and allergic rhinitis. Our study supports the use of a continuous noncensored indicator of airway responsiveness, such as the slope of the methacholine dose-response curve, in clinical practice and research because it showed clear advantages over PD20.

  • 42. Marcon, Alessandro
    et al.
    Corsico, Angelo
    Cazzoletti, Lucia
    Bugiani, Massimiliano
    Accordini, Simone
    Almar, Enrique
    Cerveri, Isa
    Gislason, David
    Gulsvik, Amund
    Janson, Christer
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Jarvis, Deborah
    Martínez-Moratalla, Jesús
    Pin, Isabelle
    de Marco, Roberto
    Body mass index, weight gain, and other determinants of lung function decline in adult asthma2009Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 123, nr 5, s. 1069-1074Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: Little is known about factors associated with lung function decline in asthma. OBJECTIVE: To identify the determinants of FEV(1) decline in adults with asthma with and without airflow obstruction at baseline. METHODS: An international cohort of 638 subjects with asthma (20-44 years old) was identified in the European Community Respiratory Health Survey (1991-1993) and followed up from 1998 to 2002. Spirometry was performed on both occasions. FEV(1) decline was related to potential determinants evaluated at baseline and during the follow-up by random intercept linear regression models. The analyses were stratified by the presence of airflow obstruction (FEV(1)/forced vital capacity < 0.70) at baseline. RESULTS: In the group of individuals without airflow obstruction (n = 544), a faster FEV(1) decline was observed for subjects with intermediate body mass index (BMI) than for lean and obese subjects. FEV(1) decline was associated with weight gain independently of baseline BMI, and this association was stronger in men (20; 95% CI, 10-30, mL/y/kg gained) than in women (6; 95% CI, 1-11, mL/y). In the group of individuals with airflow obstruction (n = 94), the absence of allergen sensitization and a low BMI at baseline were associated with a faster FEV(1) decline, whereas weight gain was not associated with decline. CONCLUSIONS: The detrimental effect of weight gain on FEV(1) decline is particularly relevant in subjects with asthma who still do not have an established airflow obstruction. Our findings support the importance of weight management in asthma and recommend weight loss in overweight or obese individuals with asthma.

  • 43.
    Maric, Jovana
    et al.
    Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria;Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Ravindran, Avinash
    Karolinska Inst, Dept Med, Immunol & Allergy Unit, Stockholm, Sweden.
    Mazzurana, Luca
    Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Björklund, Åsa K.
    Uppsala universitet, Teknisk-naturvetenskapliga vetenskapsområdet, Biologiska sektionen, Institutionen för cell- och molekylärbiologi, Molekylär evolution. Uppsala universitet, Science for Life Laboratory, SciLifeLab.
    Van Acker, Aline
    Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Rao, Anna
    Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Friberg, Danielle
    Karolinska Univ Hosp, Dept Otorhinolaryngol, Stockholm, Sweden;Karolinska Inst, CLINTEC, Stockholm, Sweden.
    Dahlen, Sven-Erik
    Karolinska Inst, Inst Environm Med, Expt Asthma & Allergy Res, Stockholm, Sweden.
    Heinemann, Akos
    Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria.
    Konya, Viktoria
    Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria;Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Mjösberg, Jenny
    Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden;Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden.
    Prostaglandin E-2 suppresses human group 2 innate lymphoid cell function2018Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 141, nr 5, s. 1761-1773.e6Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Group 2 innate lymphoid cells (ILC2s) are involved in the initial phase of type 2 inflammation and can amplify allergic immune responses by orchestrating other type 2 immune cells. Prostaglandin (PG) E-2 is a bioactive lipid that plays protective roles in the lung, particularly during allergic inflammation.

    Objective: We set out to investigate how PGE(2) regulates human ILC2 function.

    Methods: The effects of PGE(2) on human ILC2 proliferation and intracellular cytokine and transcription factor expression were assessed by means of flow cytometry. Cytokine production was measured by using ELISA, and real-time quantitative PCR was performed to detect PGE(2) receptor expression.

    Results: PGE(2) inhibited GATA-3 expression, as well as production of the type 2 cytokines IL-5 and IL-13, from human tonsillar and blood ILC2s in response to stimulation with a combination of IL-25, IL-33, thymic stromal lymphopoietin, and IL-2. Furthermore, PGE(2) downregulated the expression of IL-2 receptor alpha (CD25). In line with this observation, PGE(2) decreased ILC2 proliferation. These effects were mediated by the combined action of E-type prostanoid receptor (EP) 2 and EP4 receptors, which were specifically expressed on ILC2s.

    Conclusion: Our findings reveal that PGE(2) limits ILC2 activation and propose that selective EP2 and EP4 receptor agonists might serve as a promising therapeutic approach in treating allergic diseases by suppressing ILC2 function.

  • 44.
    Maric, Jovana
    et al.
    Med Univ Graz, Otto Loewi Res Ctr, Pharmacol Sect, Graz, Austria;BioTechMed, Graz, Austria;Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Ravindran, Avinash
    Karolinska Inst, Dept Med, Immunol & Allergy Unit, Solna, Sweden;Karolinska Univ Hosp, Clin Immunol & Transfus Med, Stockholm, Sweden.
    Mazzurana, Luca
    Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Van Acker, Aline
    Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Rao, Anna
    Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Kokkinou, Efthymia
    Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Ekoff, Maria
    Karolinska Inst, Dept Med, Immunol & Allergy Unit, Solna, Sweden;Karolinska Univ Hosp, Clin Immunol & Transfus Med, Stockholm, Sweden.
    Thomas, Dominique
    Goethe Univ Frankfurt, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, Frankfurt, Germany.
    Fauland, Alexander
    Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, Stockholm, Sweden.
    Nilsson, Gunnar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Hematologi. Karolinska Inst, Dept Med, Immunol & Allergy Unit, Solna, Sweden;Karolinska Univ Hosp, Clin Immunol & Transfus Med, Stockholm, Sweden.
    Wheelock, Craig E.
    Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, Stockholm, Sweden.
    Dahlen, Sven-Erik
    Karolinska Inst, Inst Environm Med, Expt Asthma & Allergy Res, Stockholm, Sweden.
    Ferreiros, Nerea
    Goethe Univ Frankfurt, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, Frankfurt, Germany.
    Geisslinger, Gerd
    Goethe Univ Frankfurt, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, Frankfurt, Germany;Fraunhofer Inst Mol Biol & Appl Ecol IME, Project Grp Translat Med & Pharmacol TMP, Frankfurt, Germany.
    Friberg, Danielle
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kirurgiska vetenskaper, Öron-, näs- och halssjukdomar. Karolinska Inst, Dept Clin Sci Intervent & Technol, CLINTEC, Stockholm, Sweden.
    Heinemann, Akos
    Med Univ Graz, Otto Loewi Res Ctr, Pharmacol Sect, Graz, Austria;BioTechMed, Graz, Austria.
    Konya, Viktoria
    Med Univ Graz, Otto Loewi Res Ctr, Pharmacol Sect, Graz, Austria;BioTechMed, Graz, Austria;Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden.
    Mjosberg, Jenny
    Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden;Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden.
    Cytokine-induced endogenous production of prostaglandin D-2 is essential for human group 2 innate lymphoid cell activation2019Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 143, nr 6, s. 2202-2214.e5Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Objective: We set out to examine PG production in human ILC2s and the implications of such endogenous production on ILC2 function. Methods: The effects of the COX-1/2 inhibitor flurbiprofen, the hematopoietic prostaglandin D2 synthase (HPGDS) inhibitor KMN698, and the CRTH2 antagonist CAY10471 on human ILC2s were determined by assessing receptor and transcription factor expression, cytokine production, and gene expression with flow cytometry, ELISA, and quantitative RT-PCR, respectively. Concentrations of lipid mediators were measured by using liquid chromatography-tandem mass spectrometry and ELISA. Results: We show that ILC2s constitutively express HPGDS and upregulate COX-2 upon IL-2, IL-25, and IL-33 plus thymic stromal lymphopoietin stimulation. Consequently, PGD2 and its metabolites can be detected in ILC2 supernatants. We reveal that endogenously produced PGD2 is essential in cytokine-induced ILC2 activation because blocking of the COX-1/2 or HPGDS enzymes or the CRTH2 receptor abolishes ILC2 responses. Conclusion: PGD2 produced by ILC2s is, in a paracrine/autocrine manner, essential in cytokine-induced ILC2 activation. Hence we provide the detailed mechanism behind how CRTH2 antagonists represent promising therapeutic tools for allergic diseases by controlling ILC2 function.

  • 45.
    Mascialino, Barbara
    et al.
    Thermo Fisher Sci, Uppsala, Sweden.
    Yang, Brian
    Thermo Fisher Sci, Portage, MI USA.
    Borres, Magnus P
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Forskargrupper (Inst. för kvinnor och barns hälsa), Pediatrisk inflammationsforskning. Thermo Fisher Sci, Uppsala, Sweden.
    Screening With Serology Testing Children With Asthma Could Contribute To Substantial Cost Savings To US Payors: A Population-Based Simulation Study2019Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 143, nr 2, s. AB222-AB222, artikkel-id 675Artikkel i tidsskrift (Annet vitenskapelig)
  • 46. Matheson, Melanie Claire
    et al.
    Dharmage, Shyamali Chandrika
    Abramson, Michael John
    Walters, Eugene Haydn
    Sunyer, Jordi
    de Marco, Roberto
    Leynaert, Benedicte
    Heinrich, Joachim
    Jarvis, Deborah
    Norbäck, Dan
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Arbets- och miljömedicin.
    Raherison, Chantal
    Wjst, Matthias
    Svanes, Cecilie
    Early-life risk factors and incidence of rhinitis: Results from the European Community Respiratory Health Study - an international population-based cohort study2011Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 128, nr 4, s. 816-823.e5Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Rhinitis is an increasingly common condition with a heavy health care burden, but relatively little is known about its risk factors.

    Objective: To examine the association between early-life factors and the development of rhinitis in the European Community Respiratory Health Study (ECRHS).

    Methods: In 1992-1994, community-based samples of 20-44-year-old people were recruited from 48 centers in 22 countries. On average, 8.9 years later, 28 centers reinvestigated their samples. Onset of rhinitis was reported by 8486 participants in interviewer-led questionnaires. Cox regression was used to assess independent predictors of rhinitis at ages <= 5, 6-10, 11-20, and >= 21 years.

    Results: The crude lifelong incidence of rhinitis was 7.00/1000/year (men) and 7.95/1000/year (women) (P = .002). Women developed less rhinitis in later childhood (hazard ratios [HR], 0.63; 95% CI, 0.47-0.85) and more rhinitis in adulthood (HR, 1.36; 95% CI, 1.11-1.66) than did men. In atopic subjects, siblings were associated with lower risk of rhinitis throughout life (pooled HR, 0.94; 95% CI, 0.91-0.98 per 1 sibling). Early contact with children in the family or day care was associated with less incidence of rhinitis, predominantly before age 5 years (HR, 0.84; 95% CI, 0.72-0.99). Early childhood pets or growing up on a farm was associated with less incidence of rhinitis in adolescence (HR, 0.50; 95% CI, 0.37-0.68). Combining these factors showed evidence of a dose-response relationship (trend P = .0001).

    Conclusions: Gender is a strong risk factor for rhinitis, with age patterns varying according to atopic status. Protective effects of early contact with children and animals were suggested for incident rhinitis, with risk patterns varying by age window and atopic status.

  • 47.
    Melo, Fabio R.
    et al.
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinsk biokemi och mikrobiologi.
    Wallerman, Ola
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinsk biokemi och mikrobiologi.
    Paivandy, Aida
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinsk biokemi och mikrobiologi.
    Calounova, Gabriela
    Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden..
    Gustafson, Ann-Marie
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinsk biokemi och mikrobiologi.
    Sabari, Benjamin R.
    Rockefeller Univ, Lab Chromatin Biol & Epigenet, 1230 York Ave, New York, NY 10021 USA..
    Zabucchi, Giuliano
    Univ Trieste, Dept Life Sci, Trieste, Italy..
    Allis, C. David
    Rockefeller Univ, Lab Chromatin Biol & Epigenet, 1230 York Ave, New York, NY 10021 USA..
    Pejler, Gunnar
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinsk biokemi och mikrobiologi. Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden..
    Tryptase-catalyzed core histone truncation: A novel epigenetic regulatory mechanism in mast cells2017Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 140, nr 2, s. 474-485Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    Background: Mast cells are key effector cells in allergic reactions. When activated to degranulate, they release a plethora of bioactive compounds from their secretory granules, including mast cell-restricted proteases such as tryptase. In a previous study, we showed that tryptase, in addition to its intragranular location, can be found within the nuclei of mast cells where it truncates core histones at their N-terminal ends. Objective: Considering that the N-terminal portions of the core histones constitute sites for posttranslational modifications of major epigenetic impact, we evaluated whether histone truncation by tryptase could have an impact on epigenetic events in mast cells. Methods: Mast cells were cultured from wild-type and tryptase null mice, followed by an assessment of their profile of epigenetic histone modifications and their phenotypic characteristics. Results: We show that tryptase truncates nucleosomal histone 3 and histone 2B (H2B) and that its absence results in accumulation of the epigenetic mark, lysine 5-acetylated H2B. Intriguingly, the accumulation of lysine 5-acetylated H2B was cell age-dependent and was associated with a profound upregulation of markers of non-mast cell lineages, loss of proliferative control, chromatin remodeling as well as extensive morphological alterations. Conclusions: These findings introduce tryptase-catalyzed histone clipping as a novel epigenetic regulatory mechanism, which in the mast cell context may be crucial for maintaining cellular identity.

  • 48.
    Michils, Alain
    et al.
    Erasme Univ Hosp, Brussels, Belgium..
    Haccuria, Amaryllis
    Erasme Univ Hosp, Brussels, Belgium..
    Malinovschi, Andrei
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Lungmedicin och allergologi.
    Van Muylem, Alain
    Erasme Univ Hosp, Brussels, Belgium..
    A Common Pattern of Peripheral Airway Responsiveness in Asthma and Allergic Rhinitis2017Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 139, nr 2, s. AB4-AB4Artikkel i tidsskrift (Fagfellevurdert)
  • 49. Michils, Alain
    et al.
    Malinovschi, Andrei
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Klinisk fysiologi.
    Haccuria, Amaryllis
    Michiels, Sebastien
    Van Muylem, Alain
    Different patterns of exhaled nitric oxide response to β2-agonists in asthmatic patients according to the site of bronchodilation2016Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 137, nr 3, s. 806-812Artikkel i tidsskrift (Fagfellevurdert)
    Abstract [en]

    BACKGROUND: In asthmatic patients undergoing airway challenge, fraction of exhaled nitric oxide (Feno) levels decrease after bronchoconstriction. In contrast, model simulations have predicted both decreased and increased Feno levels after bronchodilation, depending on the site of airway obstruction relief.

    OBJECTIVE: We sought to investigate whether β2-agonists might induce divergent effects on Feno values in asthmatic patients as a result of airway obstruction relief occurring at different lung depths.

    METHODS: Feno, FEV1, and the slope of phase III of the single-breath washout test (S) of He (SHe) and sulfur hexafluoride (SSF6) were measured in 68 asthmatic patients before and after salbutamol inhalation. SHe and SSF6 decreases reflected preacinar and intra-acinar obstruction relief, respectively. Changes (Δ) were expressed as a percentage from the baseline.

    RESULTS: No Feno change (|ΔFeno| ≤ 10%) was found in 16 patients (mean [SD]: 2.5% [5.2%]; ie, Feno= group); a ΔFeno value of greater than 10% was found in 23 patients (31.7% [20.3%]; ie, the Feno+ group); and a ΔFeno value of less than -10% was found in 29 patients (-31.5% [17.3%]; ie, the Feno- group). All groups had similar ΔFEV1 values. In the Feno= group neither SHe nor SSF6 changed, in the Feno+ group only SHe decreased significantly (-21.8% [SD 28.5%], P = .03), and in the Feno- group both SHe (-29.8% [24.0%], P < .001) and SSF6 (-27.2% [23.3%], P < .001) decreased.

    DISCUSSION: Three Feno behaviors were observed in response to β2-agonists: a decrease likely caused by relief of an intra-acinar airway obstruction that we propose reflects amplification of nitric oxide back-diffusion, an increase likely associated with a predominant dilation up to the preacinar airways, and Feno stability when obstruction relief involved predominantly the central airways. In combination, these results suggest a new role for Feno in identifying the site of airway obstruction in asthmatic patients.

  • 50.
    Nagao, Mizuho
    et al.
    Mie Natl Hosp, Tsu, Mie, Japan..
    Ekoff, Helena
    ThermoFisher Sci, Uppsala, Sweden..
    Borres, Magnus
    Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Forskargrupper (Inst. för kvinnor och barns hälsa), Pediatrisk inflammationsforskning. ThermoFisher Sci, Uppsala, Sweden..
    Sjolander, Anders
    Phadia AB, Uppsala, Sweden..
    Fujisawa, Takao
    Mie Natl Hosp, Tsu, Mie, Japan..
    Discrimination Between Asthmatic and Healthy Children Using Eosinophil Derived Neurotoxin is Independent of Blood Sample Matrix2018Inngår i: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 141, nr 2, s. AB102-AB102Artikkel i tidsskrift (Annet vitenskapelig)
12 1 - 50 of 73
RefereraExporteraLink til resultatlisten
Permanent link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf